Skip to navigation bar Skip to breadcrumbs Skip to page content
Envelope icon E-mail Updates Teal square Text size:  a A A

Breast Cancer: Medications for Risk Reduction

Release Date: September 2013

Recommendation Summary

Summary of Recommendations and Evidence

PopulationRecommendationGrade
(What's This?)
Women, Increased Risk for Breast Cancer

The USPSTF recommends that clinicians engage in shared, informed decision making with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxifene. 

The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.
Women, Not at Increased Risk for Breast Cancer

The USPSTF recommends against the routine use of medications, such as tamoxifen or raloxifene, for risk reduction of primary breast cancer in women who are not at increased risk for breast cancer. 

The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits

Go to the Clinical Considerations for additional information about risk factors.

Clinical Summary

Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice.

This summary is intended for use by primary care clinicians.

 
Current as of: September 2013

Internet Citation: Recommendation Summary. U.S. Preventive Services Task Force. September 2014.
http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/breast-cancer-medications-for-risk-reduction

USPSTF Program Office Small blue square bullet icon  540 Gaither Road, Rockville, MD 20850